Cancer Monoclonal Antibody Partnering Terms and Agreements

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in cancer monoclonal antibody dealmaking

2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Big pharma cancer monoclonal antibody dealmaking activity
2.4. Big biotech cancer monoclonal antibody dealmaking activity
2.5. Most active in cancer monoclonal antibody partnering
2.6. Cancer monoclonal antibody partnering by deal type
2.7. Cancer monoclonal antibody partnering by stage of development
2.8. Cancer monoclonal antibody partnering by cancer indication
2.9. Cancer monoclonal antibody partnering by antibody type
2.10. Disclosed deal terms for cancer monoclonal antibody partnering
2.10.1 Cancer monoclonal antibody partnering headline values
2.10.2 Cancer monoclonal antibody deal upfront payments
2.10.3 Cancer monoclonal antibody deal milestone payments
2.10.4 Cancer monoclonal antibody royalty rates

Chapter 3 – Leading cancer monoclonal antibody deals

3.1. Introduction
3.2. Top cancer monoclonal antibody deals by value

Chapter 4 – Big pharma cancer monoclonal antibody deals

4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma cancer monoclonal antibody partnering company profiles
   Abbott                                      Daichi Sankyo                                      Novartis
   Actavis                                     Eli Lilly                                           Novo Nordisk
   Amgen                                       Fresenius                                          Otsuka
   Astellas                                    Gilead Sciences                                    Pfizer
   AstraZeneca                                 GlaxoSmithKline                                    Roche
   Bayer                                       Johnson & Johnson                                  Sanofi
   Biogen Idec                                 Janssen Biotech                                   Sanofi-Aventis
   Boehringer Ingelheim                        Janssen Pharmaceutica NV                          Servier
   Bristol-Myers Squibb                       Menarini                                           Takeda
   Celgene                                     Merck & Co                                         Teva
   CSL                                         Merck KGaA                                        UCB

Chapter 5 – Big biotech cancer monoclonal antibody deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech cancer monoclonal antibody partnering company profiles
   Alexion Pharmaceuticals                       Novo Nordisk
   Biocon                                       PDL BioPharma
   Emergent BioSolutions                        Seattle Genetics
   Genmab                                       Spectrum Pharmaceuticals
   LFB Group                                    Swedish Orphan Biovitrum
   Morphosys
Chapter 6 – Cancer monoclonal antibody dealmaking directory

6.1. Introduction
6.2. Company A-Z
6.3. By stage of development
   Discovery
   Formulation
   Marketed
   Phase I
   Phase II
   Phase III
   Preclinical
   Regulatory
6.4. By deal type
   Asset purchase
   Assignment
   Bigpharma outlicensing
   Co-development
   Collaborative R&D
   Co-market
   Contract service
   Co-promotion
   CRADA
   Cross-licensing
   Development
   Distribution
   Equity purchase
   Evaluation
   Grant
   Joint venture
   Licensing
   Loan
   Manufacturing
   Marketing
   Material transfer
   Option
   Promotion
   Research
   Settlement
   Spin out
   Sub-license
   Supply
   Technology transfer
   Termination
   6.5. By oncology therapy area
   6.6. By monoclonal antibody type

Chapter 7 – Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 – Deal type definitions
Appendix 2 – Example monoclonal antibody cancer partnering agreement

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Technology Reports
Order Form – Therapy Reports

Table of figures

Figure 1: Cancer monoclonal antibody partnering since 2007
Figure 2: Bigpharma – top 50 – cancer monoclonal antibody deals 2007 to 2013
Figure 3: Bigpharma cancer monoclonal antibody deal frequency – 2007 to 2013
Figure 4: Big biotech – top 50 – cancer monoclonal antibody deals 2007 to 2013
Figure 5: Big biotech cancer monoclonal antibody deal frequency – 2007 to 2013
Figure 6: Active cancer monoclonal antibody dealmaking activity – 2007 to 2013
Figure 6: Cancer monoclonal antibody partnering by deal type since 2007
Figure 8: Cancer monoclonal antibody partnering by stage of development since 2007
Figure 8: Monoclonal antibody partnering by oncology target since 2007
Figure 9: Monoclonal antibody partnering by type since 2007
Figure 11: Cancer monoclonal antibody deals with a headline value – by stage of development
Figure 12: Cancer monoclonal antibody deal headline value distribution, US$million – discovery stage
Figure 13: Cancer monoclonal antibody deal headline value distribution, US$million – preclinical stage
Figure 14: Cancer monoclonal antibody deal headline value distribution, US$million – phase I stage
Figure 15: Cancer monoclonal antibody deal headline value distribution, US$million – phase II stage
Figure 16: Cancer monoclonal antibody deal headline value distribution, US$million – phase III stage
Figure 17: Cancer monoclonal antibody deal headline value distribution, US$million – regulatory stage
Figure 18: Cancer monoclonal antibody deal headline value distribution, US$million – marketed stage
Figure 19: Cancer monoclonal antibody deal headline value – median value by stage of development
Figure 20: Cancer monoclonal antibody deals with upfront payment values – by stage of development
Figure 21: Cancer monoclonal antibody deal upfront distribution, US$million – discovery stage
Figure 22: Cancer monoclonal antibody deal upfront value distribution, US$million – preclinical stage